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Previews‘‘clock-controlled genes’’ (CCGs). The
‘‘tethering’’ mechanism also allows for
‘‘modular’’ flexibility between cell types
expressing different anchor proteins. The
RORs display a similar profile to Rev-
erbs in terms of a very distinctive function
regulating the clock, but additional spe-
cific roles in the regulation of develop-
ment, immune function, etc., exist. It is
possible that RORs operate with a similar
segregation of function, but future work
will be required to address this possibility.
We have been intrigued by the distinct
activities of drugs targeting these two
classes of NRs. If the predominant mech-
anism of action of these receptors were
via direct DNA binding via recognition of
a RORE/RevDR2, then targeting them
should have similar outcomes with Rev-
erb activators acting similar to ROR
inhibitors. However, this has not been
observed in many cases. For example,
Rev-erb agonists (Banerjee et al., 2014),
but not RORa/g inverse agonists (T.P.B.,
unpublished data), are anxiolytic and
induce wakefulness. The research by
Zhang et al. (2015) suggests that most
genes targeted by Rev-erb are regulated
independently of the DBD and are thus198 Cell Metabolism 22, August 4, 2015 ª201also regulated independently of competi-
tion from RORs. Considerable differences
between the actions of these drugs are
therefore expected. Zhang et al. (2015)
also suggest that, due to the distinct reg-
ulatory mechanisms, it may be possible to
pharmacologically target DBD-indepen-
dent Rev-erb pathways while sparing the
DBD-dependent pathways, providing for
a drug avoiding general effects on the
circadian clock. This would not be a
trivial undertaking given that we typically
target Rev-erb’s ligand binding domain.
It is also unclear whether one could
modulate DBP-dependent and -indepen-
dent pathways independently with our
current understanding of NR drug devel-
opment. Finally, it is fascinating to specu-
late that we could pharmacologically
target specific tissues using synthetic
Rev-erb ligands designed to modulate
tissue- specific Rev-erb/tethered partner
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Two articles in this issue (Intlekofer et al., 2015; Oldham et al., 2015) show a newmetabolic pathway regulated
by hypoxia, but independently of HIF1 or HIF2. L-2-hydroxyglutarate, produced in hypoxia by malate dehy-
drogenases and LDHA, is a potent inhibitor of KDM4C, and through redox stress reduces glycolysis.A key step in the Krebs cycle is the
conversion of isocitrate to 2-oxoglutarate,
and thereafter to succinate. Mutations
in isocitrate dehydogenases IDH1 and
IDH2 result in conversion of 2-oxogluta-
rate (also known as alpha-ketoglutarate)
to D(R)-2-hydroxyglutarate, an oncome-
tabolite that can inhibit enzymes that use2-oxoglutarate as a cofactor with oxygen
(Losman and Kaelin, 2013). These are
dioxygenases, which include TET1 and
TET2, enzymes that modify 5-methylcyto-
sine residues in DNA and hence gene
transcription (Figure 1).
Two papers published in this issue
(Oldham et al., 2015; Intlekofer et al.,2015) describe another metabolite, a
normal product of 2-oxoglutarate meta-
bolism, the L(S)-2-hydroxyglutarate iso-
mer. Thismetabolite was previously noted
as a product of IDH in hypoxia, but its
role was unknown. These papers pre-
sent evidence of increased production
of L-2-hydroxyglutarate in hypoxia. The
Figure 1. Pathways of 2-Oxoglutarate Metabolism
Isocitrate dehydrogenases 1 and 2 reversibly convert isocitrate to 2-oxoglutarate generating NADPH.
Mutations in IDH1 and IDH2 (mIDH) result in conversion of 2-oxoglutarate to D[R]-2-hydroxyglutarate.
This can competitively inhibit TET1 and TET2 but activate other 2-dioxygenases such as PDH2. D-2-hy-
droxyglutarate is metabolized by D2HGDH. Glutamine is the main source for 2-oxoglutarate in hypoxia.
Oxoglutarate analogs provide intracellular oxoglutarate. Different oxoglutarate analogs produce different
results; for example, DKMGwas effective alone, whereas TFMB 2-OG required inhibition of ametabolizing
enzyme, OGDHC, which breaks down oxoglutarate, with the inhibitor alpha-keto-beta-methylvaleric
acid, KMV.
In the current two papers, it was shown that hypoxia generates L-2-hydroxyglutarate. This involves
utilization of oxoglutarate by other enzymes such as LDHA, MDH1, and MDH2. In contrast to D-2-oxoglu-
tarate, L-2-hydroxyglutarate inhibits PHD2 and was shown to inhibit KDM4C.
Redox stress is generated by the L-2-hydroxyglutarate. Suppression of the enzyme L2HGDH, which
metabolizes L-2-hydroxyglutarate, increases the effects. Recycling of L-2-hydroxyglutarate with 2-oxo-
glutarate by the L2HGDH can maintain NADH levels.
Myc has also been shown to upregulate the production of 2-hydroxyglutarate, but in this case through the
enzyme ADHFE1 aldehyde dehydrogenase iron-containing enzyme 1.
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Previewsaccumulation of the metabolite is several
fold and there is also a small induction of
D-2-hydroxyglutarate. Both reports use
cancer cell lines, but in particular, Oldham
et al. (2015) focuses on endothelial cells
and normal cell populations. This is not a
cancer-specific effect, but may be more
marked in cancer cell lines.
Surprisingly, both papers showed that
HIF1a had onlyminor effect on this hypox-
ia-induced metabolite change, and if any-
thing, there was a small increase in the
pathway when HIF1a was inhibited, and
there was no effect of HIF2a knockdown
(Oldham et al., 2015; Intlekofer et al.,
2015). It is very surprising that HIF1a
has little effect because one of the major
mechanisms of this shift in Krebs cycle in
hypoxia is regulation of pyruvate dehydro-
genase kinase and phosphorylation of
pyruvate dehydrogenase, which causes
almost immediate rapid reduction in flux
through the Krebs cycle. Thus, the mech-anisms by which hypoxia induces the up-
regulation of this metabolite need further
elucidation.
Both articles showed that 2-oxogluta-
rate membrane permeable precursors
could enhance the effect, although in the
case of the Intlekofer et al (2015) report,
this is achieved by the precursor alone
(dimethyl-alpha-ketoglutarate), whereas
Oldham et al. (2015) required an inhibitor
of an enzyme that degrades 2-oxogluta-
rate (OGDHC and alpha-keto-beta-meth-
ylvaleric acid), perhaps because of a
different precursor, 3-trifluoromethylben-
zyl-a-ketoglutarate ester (TFMB-2OG).
Major differences between the D and
the L isoforms exist in that the D form in-
hibits the TETenzymes, but it is also a sub-
strate for the prolyl hydroxylase domain
2 (PHD2) or EGLN1 enzymes, preventing
HIF upregulation. In contrast, the Lmetab-
olite inhibits PHD2 and TET1 and is indeed
more potent than the D isoform againstCell Metabolism 2TET enzymes, producing a rather different
biological effect, and potentially affecting
HIF1a driven gene regulation (Chowdhury
et al., 2011).
However, the downstream pathways
investigated in the two papers differ mark-
edly. Intlekofer et al. ( 2015) focused on the
effects on histone demethylation, whereas
Oldham et al. (2015) described effects
on transcription of genes downstream of
HIF1a, but in particular, changes in the
redox regulation in the cells. L-2-hydroxy-
glutarate inhibited the H3K9me3 demethy-
lase KDM4C. Considering the number of
dioxygenases and that many have roles
in chromatin modification (Salminen et al.,
2015), this provides an important further
mechanism for fine-tuning the hypoxia
response in different cells and tissues.
Depending on the fold induction of this
metabolite, there may be far greater het-
erogeneity and adaptation than previously
realized (Choudhry et al., 2014).
The redox changes were associated
with reduction of glycolysis and the shift
in Krebs cycle to glycolysis. However,
most of the latter effects were generated
by manipulating L-2-hydroxyglutarate
levels, rather than by hypoxia.
Both reports agree that the source
of L-2-hydroxyglutarate is not IDH1 and
IDH2, but metabolism by MDH1 and
MDH2. In Intlekofer et al. (2015), a much
more important role of LDHA is shown
and no effect of LDHB. Since the major-
ity of the effects could be attributed to
LDHA in the Intlekofer et al. (2015) report
and to MDH2 in the Oldham et al. (2015)
report, the relevant roles of these en-
zymes in different cell types needs further
clarification.
Successful inhibition of mutant IDH1
and IDH2 has shown the continued
dependence on cells that grown in the
presence of these mutations for R-2-hy-
droxyglutarate. It would be much harder
to make inhibitors that would be success-
ful for the L-2-hydroxyglutarate, since
attempts to produce useful inhibitors of
LDHA have not been successful, and
there are major concerns about produc-
ing inhibitors of mitochondrial enzymes
and normal tissue toxicity.
However, the glutamine pathway is
clearly important under hypoxia, feeding
into this metabolic process, and, with the
availability of small molecule inhibitors of
glutaminase (Xiang et al., 2015) combined
with the ability to deprive tumor cells of2, August 4, 2015 ª2015 Elsevier Inc. 199
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Previewsglutamate, may be an important therapeu-
tic approach (Emadi et al., 2014).MYC also
drives this pathway, although in those
studies another enzyme was responsible,
the mitochondrial aldehyde dehydroge-
nase iron-containing enzyme 1 (ADHFE1)
and IDH2 (Terunuma et al., 2014).Whether
both L and D isoforms were present is
not clear, as knockdown of D2HGDH did
not affect levels, yet IDH2 knockdown
prevented their generation. Tumors with
high 2-hydroxyglutarate or DNA methyl-
ation patterns had a worse prognosis and
high glutaminase expression. It was also
shown thatglutaminewas themainprecur-
sor for the 2-hydroxyglutarate. The studies
need to be repeated in hypoxia now.
The levels of L-2-hydroxyglutarate or
the indirect effects on H3K9me3 methyl-
ation could be useful monitors of in vivo
hypoxia metabolism and could help clas-
sify hypoxia areas of tumors in a different
way to using HIF1 or carbonic anhy-
drase 9 staining or pimonidazole binding
(Jubb et al., 2010). Classification of hyp-
oxia in tumors may be helpful for future
personalization of radiotherapy and hyp-
oxia-activated prodrugs. Intlekofer et al.
(2015) indeed showed that upregulation200 Cell Metabolism 22, August 4, 2015 ª201of H3K9me3 correlated with HIF1 in glio-
blastoma, but the time course of reversal
of L-2-hydroxyglutarate after reoxyge-
nation or demethylation of H3K9me3 is
unclear and needs further investigation.
For example, if there is discordance of
overlap between HIF1a and these path-
ways in other tumor types, deciphering
which of the biological pathways is active
in a tumor is important. Individual tumors
show great heterogeneity in the extent
of hypoxic areas and genes expressed
in them, and some with low HIF1a
expression could potentially be driven by
this metabolic pathway and would pro-
duce different types of hypoxia biology,
relevant to interaction with drugs and
radiation.ACKNOWLEDGMENTS
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High adipose expression of NNMT, an enzyme that converts nicotinamide to 1-methyl-nicotinamide, corre-
lates with adiposity. Though murine NNMT knockdown in fat and liver prevents weight gain on high-fat
diet, Hong et al. (2015) now show that high hepatic expression of NNMT improves lipid parameters via
SIRT1 stabilization.NAD+ is the central coenzyme for the
oxidation of fuel and for interconversion
of different classes of metabolites,
including the conversion of carbohy-
drates to lipids (Belenky et al., 2007).
NAD+ is typically reduced to NADH in
fuel oxidation steps, whereas NADPH isreoxidized to NADP+ in lipogenic reac-
tions. Cells control major processes
such as glycolysis, gluconeogenesis,
and lipogenesis, in part, with changes in
gene expression programs. Several such
programs are modulated by sirtuin 1
(SIRT1), an NAD+-dependent proteinlysine deacetylase (Chang and Guarente,
2014). SIRT1 is not a redox enzyme
but rather an NAD+-consuming enzyme,
whose activities as a regulator of gene
expression and protein function link lysine
deacetylation to the turnover of NAD+.
The products of SIRT1 are a deacetylated
